Venatorx, Melinta's BARDA-funded antibiotic combo falls short with manufacturing-related rejection

As the World Health Organization and others pine for new innovation in antibiotics, a combination option from Venatorx Pharmaceuticals and Melinta Therapeutics won't be able to help out the cause anytime soon as manufacturing issues have led to an FDA rejection.